The "sifilis-" for the prevention and treatment of dysbacteriosis and inflammatory diseases of organs of abdominal cavity and small pelvis (and its variants)
The invention relates to medicine and can be used in proctology, urology, obstetrics and gynecology, Pediatrics, gastroenterology, Oncology, therapy, surgery and other medical fields. The proposed two variants of the “Sifilis-” for treatment and prophylaxis of a dysbacteriosis, inflammatory diseases of organs of abdominal cavity and small pelvis, one of which contains one dose of Sifilis dry (VIGIL) in an amount of 1-5 doses, which additionally contains a comprehensive synthetic structural basis - tallow - 1,0 - 2,0 g and represents suppositories intended for rectal and intravaginal use. In another embodiment, the tool further comprises vitamin E (alpha-tocopherol) in an amount of 2-10 mg per one suppository. The tool provides greater absorption of lysozyme from the gut, improves the efficiency of the prevention and treatment of a dysbacteriosis. 2 S. and 1 C.p. f-crystals, 6 PL.
The invention relates to medicine and can be used in proctology, urology, obstetrics and gynecology, Pediatrics, gastroenterology, Oncology, therapy, surgery and other Asa, and functional intestinal dyskinesia, urinary and biliary tract in patients with secondary immunodeficiency and reduced nonspecific resistance is usually accompanied and complicated by dysbiotic changes in the microflora of the intestines and genitals.
This determines the need for such patients and persons at-risk groups simultaneously a comprehensive adjustment of microbiocenosis of the main habitats of the body and immunobiological reactivity.
You know the tool Sifilis (VIGIL), including liofilizirovannuu biomass of bifidobacteria and lysozyme at a ratio of 1 dose: biomass of bifidobacteria 106-108SOME, lysozyme 5-20 mg (patent RF №2071339, a 61 K 35/74, 1997).
Sifilis dry is designed for oral, local and intravaginal use for the prevention and treatment of dysbacteriosis and dysfunction of the intestine. The drug has a high clinical and bacteriological efficacy in dysbacteriosis of various origins in children and adults, stimulates the nonspecific resistance of the body, greatly increases the effectiveness of treatment of infectious-inflammatory diseases of different localization, improves re is Utri include:
partial inactivation of part of bifidobacteria and lysozyme digestive enzymes;
- relatively low stimulation factors of local immunity of the mucous membrane of the colon (cells lymphoplasmocytic infiltration, tissue level of lysozyme in the wall of the intestine) compared to the upper gastrointestinal tract (duodenum and small intestine) when using therapeutic doses of bifilosa oral;
- insufficient implementation of system immune correcting and antioxidant effect.
This may be due to the fact that, according to the literature, the absorption of exogenous lysozyme from the gut of a small - in experiments with isolated loop of the small intestine, it was about 20%. Therefore, although oral administration of bifilosa in the lumen of the gastrointestinal tract (GIT) is the rapid replenishment of lysozyme and bifidobacteria, but the increase in the initial level of serum lysozyme is made gradually, by the end of the course of biotherapy, as improve the function of cells producing endogenous lysozyme (cells Panet in the small intestine, macrophages and neutrophils in mesepisternum infiltrate SL is practical reactivity of the organism.
To eliminate these disadvantages, and when it is impossible or unwise oral administration of bifilosa (for example, when you refuse to take oral medications; in the early postoperative period during surgery on the intestines and abdominal organs; difficulty swallowing; in children and adults who are on parenteral nutrition, mechanical ventilation, etc.,), in immunocompromised patients, especially in geriatric practice, in other cases, the appropriate use of bifilosa in the form of a suppository for rectal and intravaginal administration. The convenience and ease of use of a rectal suppository, a good absorption of soluble medicinal substances in case of rectal administration, reaching 40-60%, allows for greater obscherezorbtivnymi effect of biologically active drugs to avoid their destruction by digestive enzymes and to overcome hepatic barrier that improves the efficiency of treatment. Intravaginal suppositories are also more convenient to use compared with intravaginal application of tampons with dissolved ex tempore bifilosa dry.
The present invention is sozdanii the effectiveness of treatment and prevention of dysbacteriosis, nonspecific inflammatory diseases of organs of abdominal cavity and small pelvis, including the presence of destructive and toxic-allergic reactions taking place due to lowered resistance.
To solve the problem and achieve a technical result of the proposed two variants of funds for treatment and prevention of dysbacteriosis, inflammatory diseases of organs of abdominal cavity and small pelvis, one of which contains one dose of Sifilis dry (VIGIL) in an amount of 1-5 doses, which additionally contains a comprehensive synthetic structural basis - tallow - 1,0-2,0 g and represents suppositories intended for rectal and intravaginal use. In another embodiment, the tool further comprises vitamin E (alpha-tocopherol) in an amount of 2-10 mg per one suppository.
The tool named “Sifilis-S”.
As the structural basis use tallow production of Dutch firm “Jooders Croklaan” corresponding to the previously developed VNIIRA suppozitornoj base VFS 42-1117-81, “confectionery Fats for chocolate products (solid), according to THE 9142-024-00333500-1, “Witepsol W35” Yokoi purpose Sifilis-assign 1 suppository rectally or intrawaginalno 1-2 times a day for 10-14 days.
For treatment of a dysbacteriosis, increase efficiency and improve portability of complex treatment of inflammatory and other diseases of organs of abdominal cavity and small pelvis, Sifilis-should be applied on 1 suppository 2-3 times a day for 2-3 weeks. In severe inflammatory diseases of organs of abdominal cavity and small pelvis, depending on the severity of dysbiotic changes may apply Utiliza-1 suppository 2 times a day in combination with simultaneous oral administration of Bifilosa dry for 5 doses 2 times a day for 10-14 days on the background of basic therapy of the underlying disease with subsequent continuation up to 3-4 weeks of the course biocorrection Bifilosa-(1 suppository 1-2 times per day) or oral administration of Bifilosa dry (5 doses 1-2 times a day), usually in combination with oral use of probiotics containing Lactobacillus, as well as prebiotics.
The effectiveness of the proposed tools (Sifilis-C) confirmed by clinical examples.
Patient K., Within 4 years suffer from chronic colitis and intestinal dysbiosis and chronic vaginitis. Bacteriological examination revealed kishechnika revealed a decrease in the total number of Escherichia coli, and in the vaginal microflora - the deficit of lactobacilli. Sifilis-in the form of suppositories used within 14 days of the rectum (1 suppository 2 times a day) in combination with simultaneous intravaginal application of the preparation according to the same scheme. After a course of biotherapy normalization of stool, intestinal and vaginal microflora, mild symptoms of vulvovaginitis, normalization of the level of endogenous lysozyme in the serum.
Patient P., aged 63, more than 2 years, suffering from irritable bowel syndrome for hyponatremia type on the background biliary dyskinesia, was identified dysbiosis stage II with a deficit of Escherichia coli and lactobacilli (106and 5×107CFU/g), the presence of Staphylococcus aureus (103CFU/g). There was a decline in the level of lysozyme (2.0 µg/ml at the rate of 4-6 ml) and 1- PI (23,1 IE/ml at norm 29,0 IE/ml) on the background of a sharp increase anastasopoulou activity of blood serum (EPA), which amounted to 478 IU/ml at the rate of 150 IU/ml). Sifilis With the suppositories used rectally 2 times a day for 14 days in combination with oral administration of Lactobacterin and symptomatic therapy (dicetel, allohol). On the background of Biola, reducing abdominal pain, burping, heartburn, reducing irritability, on the 7th day of normal appetite, frequency and character of stools, disappeared abdominal pain, nausea, belching, flatulence, almost normalized the psycho-emotional state. By the end of the course of biotherapy Bifilosa-With virtually indicators were normalized to the content of endogenous serum lysozyme (3.6 µg/ml) activity 1- PI (30,0 IE/ml) and EPA (182 IU/ml) in the serum; bacteriological examination of faeces revealed an increase of 1 lg content of bifidobacteria and lactobacilli, to the lower limit of normal (1×10 CFU/g) increased the total number of E. coli was not inoculated Staphylococcus aureus.
Clinical trials show that the use of the invention allows to obtain the following result:
to accelerate clinical and bacteriological cure and to provide a pronounced prophylactic effect in the intestinal and vaginal dysbacteriosis;
to improve the efficiency of complex treatment of irritable bowel syndrome, non-specific inflammatory diseases of organs of abdominal cavity and small pelvis colitis (including ulcerative colitis), enterocyte, urethritis, pyelonephritis, and others;
- to accelerate the normalization of the functional status of the gastrointestinal tract, liver, urinary tract and other organs in nonspecific inflammatory and destructive processes of various origins, including the period of convalescence after acute intestinal infections;
- to increase the effectiveness of prevention nevynashivanii pregnancy and hypogalactia women at-risk groups;
- to reduce the level anemizatsii and sensitization of the body;
- to increase the body's resistance to infections, toxic, medical, radiation and stress factors;
to improve portability and cytotoxic drug therapy in patients with inflammatory, cancer and other diseases;
- to increase the effectiveness of antibiotic therapy in infectious-inflammatory processes of various localization;
to reduce the frequency and severity of endogenous infection, inflammatory and destructive complications of surgical interventions on the organs of abdominal cavity and small pelvis, and the frequency of chronic infectious and inflammatory diseases in patients, rcoa, urological, gynecological and other inflammatory diseases and related manifestations of emotional instability in frequently ill children, pregnant women, patients with different pathologies and other persons at-risk groups.
The result of using the proposed shape is achieved due to better absorption and creation of conditions for the rapid implementation of systemic immune correcting effect lysozyme component Utiliza-rectal application, as well as with the additional inclusion of vitamin E (alpha-tocopherol).
Thus, Sifilis-is a highly effective, physiological, safe drug with strong probiotic and polyfunctional biocorrosion action that can improve the effectiveness of treatment and prevention of dysbacteriosis and inflammatory diseases, mainly abdominal cavity and small pelvis, especially against the background of reduced resistance of the organism.
Specific examples of carrying out the invention. The inventive tool - Sifilis-includes the following ingredients one suppository weighing 1-2,5 g (table. 1-6).
1. The remedy for the prevention and treatment of it is made in the form of suppositories and contains sifilis dry and structural basis - solid fat, the content of a biological product and the basics in one suppositories is 1-5 1-2 doses and g, respectively.
2. The remedy for the prevention and treatment of dysbacteriosis and inflammatory diseases of organs of abdominal cavity and small pelvis, characterized in that it is made in the form of suppositories and contains sifilis dry, structure-Foundation - solid fat and vitamin E content of these ingredients in one suppositories 1-5 doses of 1-2 g and 2-10 mg, respectively.
3. Means under item 1 or 2, characterized in that it is intended for rectal and intravaginal administration.